The Europe RNA Based Therapeutic Market would witness market growth of 14.9% CAGR during the forecast period (2021-2027).
RNA-based therapies have been investigated as a possible treatment option for difficult-to-treat disorders. The therapies are being developed using promising technologies including RNA interference technology (RNAi) and antisense technology. In addition, with the incorporation of RNAi techniques in personalized medicine and molecular diagnostics, cancer detection and therapy are currently undergoing a change. Small interfering RNAs (siRNA) or microRNAs (miRNA) can also be used for diagnostic purposes.
Because of the growing demand for RNA therapies to tackle unmet medical needs, non-profit organizations have pooled their financial resources to accelerate the development of RNA therapeutics. In addition, the growing desire for personalized medicine to improve clinical outcomes and pharmaceutical safety has supported the expansion of the RNA vaccines market. In the treatment of cancer, personalized therapy is crucial (large patient population).
Because of increased RNA research activities in collaboration with government organizations, the UK RNA-based Therapeutics and Vaccines market holds a significant position in Europe. Additionally, the number of manufacturers of RNA is increasing in Germany, owing to which, Germany holds the second largest share in Europe RNA based therapeutics and vaccines. Moreover, the increasing geriatric population across the region is another reason for the development of RNA-based therapeutics in Europe. According to the data shared by Eurostat, in 2020, more than a fifth of the EU population (20.6 percent) will be 65 or older. Between 2020 and 2100, the proportion of people aged 80 and up in the EU population is expected to increase by two and a half times, from 5.9% to 14.6 percent.
The Germany market dominated the Europe RNA Based Therapeutic Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $693.9 million by 2027. The UK market is poised to grow at a CAGR of 14% during (2021 - 2027). Additionally, The France market would exhibit a CAGR of 15.7% during (2021 - 2027).
Based on Type, the market is segmented into RNA Antisense and RNA Interference (RNAi). Based on Application, the market is segmented into Genetic disorders and Auto immune disorders. Based on End User, the market is segmented into Research Institutes and Hospitals & Clinics. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global RNA Based Therapeutic Market Size will Hit $11.4 Billion by 2027, at a CAGR of 15.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., Benitec Biopharma, Inc., Alnylam Pharmaceuticals, Inc., Sanofi S.A. (Sanofi Genzyme), Biogen, Inc., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Silence Therapeutics Plc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- RNA Antisense
- RNA Interference (RNAi)
By Application
- Genetic disorders
- Auto immune disorders
By End User
- Research Institutes
- Hospitals & Clinics
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals, Inc.
- Benitec Biopharma, Inc.
- Alnylam Pharmaceuticals, Inc.
- Sanofi S.A. (Sanofi Genzyme)
- Biogen, Inc.
- Gradalis, Inc.
- Ionis Pharmaceuticals, Inc.
- Sarepta Therapeutics, Inc.
- Silence Therapeutics Plc
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe RNA Based Therapeutic Market, by Type
1.4.2 Europe RNA Based Therapeutic Market, by Application
1.4.3 Europe RNA Based Therapeutic Market, by End User
1.4.4 Europe RNA Based Therapeutic Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2022, Jan) Leading Players
Chapter 4. Europe RNA Based Therapeutic Market by Type
4.1 Europe RNA Antisense Market by Country
4.2 Europe RNA Interference (RNAi) Market by Country
Chapter 5. Europe RNA Based Therapeutic Market by Application
5.1 Europe Genetic disorders Market by Country
5.2 Europe Auto immune disorders Market by Country
Chapter 6. Europe RNA Based Therapeutic Market by End User
6.1 Europe Research Institutes Market by Country
6.2 Europe Hospitals & Clinics Market by Country
Chapter 7. Europe RNA Based Therapeutic Market by Country
7.1 Germany RNA Based Therapeutic Market
7.1.1 Germany RNA Based Therapeutic Market by Type
7.1.2 Germany RNA Based Therapeutic Market by Application
7.1.3 Germany RNA Based Therapeutic Market by End User
7.2 UK RNA Based Therapeutic Market
7.2.1 UK RNA Based Therapeutic Market by Type
7.2.2 UK RNA Based Therapeutic Market by Application
7.2.3 UK RNA Based Therapeutic Market by End User
7.3 France RNA Based Therapeutic Market
7.3.1 France RNA Based Therapeutic Market by Type
7.3.2 France RNA Based Therapeutic Market by Application
7.3.3 France RNA Based Therapeutic Market by End User
7.4 Russia RNA Based Therapeutic Market
7.4.1 Russia RNA Based Therapeutic Market by Type
7.4.2 Russia RNA Based Therapeutic Market by Application
7.4.3 Russia RNA Based Therapeutic Market by End User
7.5 Spain RNA Based Therapeutic Market
7.5.1 Spain RNA Based Therapeutic Market by Type
7.5.2 Spain RNA Based Therapeutic Market by Application
7.5.3 Spain RNA Based Therapeutic Market by End User
7.6 Italy RNA Based Therapeutic Market
7.6.1 Italy RNA Based Therapeutic Market by Type
7.6.2 Italy RNA Based Therapeutic Market by Application
7.6.3 Italy RNA Based Therapeutic Market by End User
7.7 Rest of Europe RNA Based Therapeutic Market
7.7.1 Rest of Europe RNA Based Therapeutic Market by Type
7.7.2 Rest of Europe RNA Based Therapeutic Market by Application
7.7.3 Rest of Europe RNA Based Therapeutic Market by End User
Chapter 8. Company Profiles
8.1 Arbutus Biopharma Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.4.2 Acquisitions, Mergers and Joint Ventures:
8.2 Arrowhead Pharmaceuticals, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Benitec Biopharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.4 Alnylam Pharmaceuticals, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expense
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Approvals and Trials:
8.5 Sanofi S.A. (Sanofi Genzyme)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Biogen, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.7 Gradalis, Inc.
8.7.1 Company Overview
8.8 Ionis Pharmaceuticals, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.9 Sarepta Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.9.4 Recent strategies and developments:
8.9.4.1 Partnerships, Collaborations, and Agreements:
8.10. Silence Therapeutics Plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
TABLE 1 Europe RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 2 Europe RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– RNA Based Therapeutic Market
TABLE 4 Acquisition and Mergers– RNA Based Therapeutic Market
TABLE 5 Approvals and trials– RNA Based Therapeutic Market
TABLE 6 Europe RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 7 Europe RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 8 Europe RNA Antisense Market by Country, 2017 - 2020, USD Million
TABLE 9 Europe RNA Antisense Market by Country, 2021 - 2027, USD Million
TABLE 10 Europe RNA Interference (RNAi) Market by Country, 2017 - 2020, USD Million
TABLE 11 Europe RNA Interference (RNAi) Market by Country, 2021 - 2027, USD Million
TABLE 12 Europe RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 13 Europe RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 14 Europe Genetic disorders Market by Country, 2017 - 2020, USD Million
TABLE 15 Europe Genetic disorders Market by Country, 2021 - 2027, USD Million
TABLE 16 Europe Auto immune disorders Market by Country, 2017 - 2020, USD Million
TABLE 17 Europe Auto immune disorders Market by Country, 2021 - 2027, USD Million
TABLE 18 Europe RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 19 Europe RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 20 Europe Research Institutes Market by Country, 2017 - 2020, USD Million
TABLE 21 Europe Research Institutes Market by Country, 2021 - 2027, USD Million
TABLE 22 Europe Hospitals & Clinics Market by Country, 2017 - 2020, USD Million
TABLE 23 Europe Hospitals & Clinics Market by Country, 2021 - 2027, USD Million
TABLE 24 Europe RNA Based Therapeutic Market by Country, 2017 - 2020, USD Million
TABLE 25 Europe RNA Based Therapeutic Market by Country, 2021 - 2027, USD Million
TABLE 26 Germany RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 27 Germany RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 28 Germany RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 29 Germany RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 30 Germany RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 31 Germany RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 32 Germany RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 33 Germany RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 34 UK RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 35 UK RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 36 UK RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 37 UK RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 38 UK RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 39 UK RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 40 UK RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 41 UK RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 42 France RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 43 France RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 44 France RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 45 France RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 46 France RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 47 France RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 48 France RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 49 France RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 50 Russia RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 51 Russia RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 52 Russia RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 53 Russia RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 54 Russia RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 55 Russia RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 56 Russia RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 57 Russia RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 58 Spain RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 59 Spain RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 60 Spain RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 61 Spain RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 62 Spain RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 63 Spain RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 64 Spain RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 65 Spain RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 66 Italy RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 67 Italy RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 68 Italy RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 69 Italy RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 70 Italy RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 71 Italy RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 72 Italy RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 73 Italy RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 74 Rest of Europe RNA Based Therapeutic Market, 2017 - 2020, USD Million
TABLE 75 Rest of Europe RNA Based Therapeutic Market, 2021 - 2027, USD Million
TABLE 76 Rest of Europe RNA Based Therapeutic Market by Type, 2017 - 2020, USD Million
TABLE 77 Rest of Europe RNA Based Therapeutic Market by Type, 2021 - 2027, USD Million
TABLE 78 Rest of Europe RNA Based Therapeutic Market by Application, 2017 - 2020, USD Million
TABLE 79 Rest of Europe RNA Based Therapeutic Market by Application, 2021 - 2027, USD Million
TABLE 80 Rest of Europe RNA Based Therapeutic Market by End User, 2017 - 2020, USD Million
TABLE 81 Rest of Europe RNA Based Therapeutic Market by End User, 2021 - 2027, USD Million
TABLE 82 Key information – Arbutus Biopharma Corporation
TABLE 83 Key information – Arrowhead Pharmaceuticals, Inc.
TABLE 84 Key information – Benitec Biopharma, Inc.
TABLE 85 Key Information – Alnylam Pharmaceuticals, Inc.
TABLE 86 Key Information – Sanofi S.A.
TABLE 87 Key Information – Biogen, Inc.
TABLE 88 Key information – Gradalis, Inc.
TABLE 89 Key information – Ionis Pharmaceuticals, Inc.
TABLE 90 Key information – Sarepta Therapeutics, Inc.
TABLE 91 Key information – Silence Therapeutics plc
List of Figures
FIG 1 Methodology for the research
FIG 1 KBV Cardinal Matrix
FIG 2 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 3 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2022, Jan) Leading Players
FIG 4 Recent strategies and developments: Arbutus Biopharma Corporation
FIG 5 Recent strategies and developments: Sanofi S.A.